The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Developing safe and effective agents for the treatment of CLL
Paolo Ghia, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about the current goals in chronic lymphocytic leukemia (CLL) therapy, particularly in the development of effective and safe novel agents that may provide good clinical benefit for a time-limited period, and the issues associated with these goals. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
